About
5
Publications
277
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
29
Citations
Citations since 2017
Publications
Publications (5)
Background
In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.
Methods
The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5...
Introduction
CXD101 is a class I-selective HDAC inhibitor (HDACi)with no demonstrable activity against HDAC class II in non-clinical studies. CXD101 induces specific HDAC inhibition and subsequent to that, enhanced histone acetylation in a time and dose-dependent fashion in cell lines cells in vitro, leucocytes obtained from treated rats and dogs,...
Background
We sought to determine the maximal tolerated dose (MTD) of the novel Class I selective HDAC inhibitor
(HDACi) CXD101 in a dose escalation study in advanced solid cancer and lymphoma. A genome wide lossof function screen identified HR23B, a protein that shuttles ubiquitinated cargo proteins to the proteasome, as a
sensitivity determina...
Background
Brain metastases occur in up to 75% of patients with advanced melanoma. Most are treated with whole-brain radiotherapy (WBRT), with limited effectiveness. Vandetanib, an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and rearranged during transfection tyrosine kinases, is a potent radiosensitis...
